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MICRO-COSTING OF JUDO-THERAPY CLINICS IN JAPAN-MULTI-CENTERED COST ANALYSIS
Tarumoto N 1 , Igarashi A 2 , Tarumoto E 3 , Harada T 3 , Fukuda T 4 1 Teikyo Heisei University, Tokyo, Japan; 2 Tokyo Univ. Faculty of Pharmacy, Tokyo, Japan; 3 Tarumoto Judo-Therapy Clinic, Tokyo, Japan; 4 Tokyo University, Tokyo, Japan OBJECTIVES: In the Judo-therapeutic fi eld, their costs are partly covered by National Health Insurance System via fee-for-service reimbursement, which does not necessarily refl ect actual costs. Therefore, the actual situation of medical practice in Judo-therapy Clinics (bone-setting clinics) is analyzed by comparison between the actual costs calculated by micro-costing methods and .reimbursement cost calculated by fee-forservice system. METHODS: The basis of this study is a bidirectional evaluation of single medical intervention in terms of actual cost and reimbursed cost for single treatment with following methods: 1) All receipts are collected from the participating bone-setting clinics for a fi xed period of time; 2) Along with collection of receipts, information on the medical interventions is recorded by region with regard to "how long" and "who" performed them; 3) The tentative cost of medical intervention is calculated based on the data in 2) above and the data of wage for the engaged persons. In other words, the tentative cost is calculated as the practitioner's wage per unit time multiplied by the time consumed; 4) The cost-based amount of individual medical intervention is calculated by adding indirect costs (wage for other staff than practitioner, cost for operation/maintenance of judo-therapy clinic) to the data in 3); and 5) Standard critical paths are made for several diseases, based on which medical expense for each therapy model is calculated in terms of both receipt-based amount and costbased amount, and a comparison of amount is made between them. RESULTS: Therapies in a total of 1646 regions were recorded, based on which a comparison was made using four diseases (lumbar sprain, neck sprain, femoral contusion, back contusion) as models. The receipt-based medical expense was JPY9030 (US$100) for all diseases, while the cost-based medical expense widely varied from JPY22,057 to JPY22,950 (US$245 to US$255). CONCLUSIONS: There was a signifi cant difference between the insurance benefi t amount and the actual cost of medical intervention in judo-therapy.
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HEALTH-CARE RESOURCE UTILIZATION AND OUTCOMES ANALYSIS OF OSTEOPOROTIC HIP FRACTURES AMONG THAI POST-MENOPAUSAL WOMEN: A PILOT INVESTIGATION
Reungjarearnrung K 1 , Chonglerttham S 2 , Permsuwan U 3 1 Bumrungrad Hospital, Bangkok, Bangkok, Thailand; 2 Bumrungrad Hospital, Wattana, Bangkok, Thailand; 3 Chiang Mai University, Muang, Chiang Mai, Thailand OBJECTIVES: Facing scarce data in Thailand on hospital costs of osteoporotic fractures, we examined repeated fractures and hospital costs incurred over 1 year from a primary osteoporotic hip fracture hospitalization occurred in postmenopausal women with or without comorbidities at Bumrungrad International Hospital in Bangkok. METHODS: Hospital admissions for primary hip fracture coded ICD-10 S 72.1 in post-menopausal women, aged 55 or older, were collected from January 2007 to January 2009. The hip fracture comorbidities considered were hypertension, type 2 diabetes, cardiovascular disease and their combinations. The repeated fractures within 6 or 12 months after fi rst admission were documented. All direct medical costs were retrieved from the hospital database looking at 1-year follow-up period. Statistical analysis employed unpaired t-test, Mann-Whitney U test and multivariate analysis for comparison of outcomes, costs and correlations to comorbidities. RESULTS: A total of 59 hospital admissions for diagnosed osteoporotic primary hip fracture in postmenopausal women were screened. Patients' mean age (SD) was 74.6 (7.7) years old, the mean hospital follow-up (SD) was 246.7 (77.5) days and the mean hospitalization duration (SD) was 17.0 (12.2) days. Patients at screening with and without comorbidities had similar characteristics including the types of fractures. The group with comorbidities was at higher relative risks of repeated fractures at 6 and 12 months follow-up compared to the group without comorbidities (1.13 vs. 0.91, P = 0.016; 1.10 vs. 0.94, P = 0.273, respectively) with consequently higher health-care utilization cost with 564,300 THB/patient/year versus 374,200 THB/patient/year, P = 0.043. The cost of all type drugs for both groups was only 8-10% of the total illness cost. CONCLU-SIONS: In osteoporotic post-menopausal women admitted at hospital for primary hip fracture, comorbidities increased risks of repeated fractures hospitalization as well as hospital costs. The cost of drugs was marginal among hospital costs of osteoporosis.
PMS7 A COST-EFFECTIVENESS ANALYSIS OF OSTEOPOROSIS TREATMENT FOR FRACTURE PREVENTION IN POSTMENOPAUSAL THAI WOMEN: A COMPARISON OF SEVEN TREATMENT OPTIONS
Pongchaiyakul C 1 , Songpattanasilp T 2 , Taechakraichana N 3 1 Khon Kaen University, Muang, Khon Kaen, Thailand; 2 Phramongkutklao Hospital and College of Medicine, Ratchathewi, Bangkok, Thailand; 3 Chulalongkorn University, Pathumwan, Bangkok, Thailand OBJECTIVES: To evaluate the cost-effectiveness of bisphosphonates (alendronate, risedronate, ibandronate, zoledronic acid), raloxifene, calcitonin and strontium ranelate, with a combination of calcium and Vitamin D as comparator, for the prevention of osteoporosis-related fractures in Thai post-menopausal women.
METHODS:
A Markov state transition model with 1-year cycle length was designed to simulate the cost-effectiveness of seven osteoporosis treatment interventions, compared with calcium and vitamin D, in Thai post-menopausal women aged 50-70 years. The model health states were categorized as osteopenia/no fracture, hip fracture, vertebral fracture, post-hip fracture, post-vertebral fracture and death. Treatment effects were obtained from published literature. The analysis was conducted using a societal perspective and included direct medical, direct nonmedical and indirect costs. Uncertainty was investigated by a probabilistic Monte Carlo simulation. Treatment outcomes were measured in terms of number of fractures avoided, number of life-years gained and quality-adjusted life-years (QALY) gained. Cost-effectiveness was defi ned as an ICER of less than 300,000 Baht (an incremental cost of ≤300,000 Baht for an outcome of no fracture for 1 year). RESULTS: 1) For patients with no prior fracture (primary prevention), zoledronic acid is cost-effective at ≥65 years, alendronate, risedronate and ibandronate at ≥70 years. 2) For patients with prior vertebral fracture (secondary prevention), zoledronic acid is cost-effective at ≥50 years, alendronate, risedronate and ibandronate at ≥55 years, raloxifene and strontium ranelate at ≥60 years; and 3) For patients with prior non-vertebral fractures, zoledronic acid is cost-effective at ≥60 years, alendronate at ≥65 years, and risedronate and ibandronate at ≥70 years. CON-CLUSIONS: Zoledronic acid, followed by other bisphosphonates, is the most costeffective treatment option for both primary and secondary fracture prevention in Thai postmenopausal women with osteoporosis. These fi ndings should be implemented in the government policy for selecting appropriate anti-osteoporotic drugs and reimbursement support strategy for Thai postmenopausal women with osteoporosis.
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COST-EFFECTIVENESS OF RISEDRONATE FOR CORTICOSTEROID-INDUCED OSTEOPOROSIS IN AUSTRALIA
The University of Melbourne, Fitzroy, Victoria, Australia; 2 Sanofi -Aventis Australia Pty Limited, Macquarie Park, Australia; 3 Sanofi -Aventis Australia Pty Ltd, Macquarie Park, NSW, Australia OBJECTIVES: We sought to determine, from the Australian health-care perspective, the cost-effectiveness of the bisphosphonate risedronate, relative to placebo, in preventing vertebral fractures among patients with corticosteroid-induced osteoporosis. METHODS: A decision-analytic Markov model was developed to simulate the onset 4th Asia-Pacifi c Abstracts A559 of vertebral fractures and death among Australian patients with corticosteroid-induced osteoporosis. Age-specifi c underlying incidences of vertebral fractures and death were estimated from published data. The costs (AUD $1393 in Year 1 and AUD $34 in subsequent years) and utility (0.71) associated with a vertebral fracture were also drawn from published sources, as was the effi cacy of risedronate in reducing vertebral fracture risk (relative risk 0.43, 95% CI 0.20-0.92). The model adopted a life-time horizon and an annual discount rate of 5% was applied to both costs and years of life/QALYs lived. Multiple sensitivity analyses were undertaken with reasonable variations to key data inputs. RESULTS: The base-case incremental cost-effectiveness ratio (ICER) with a life-time horizon was AUD $18,085 per QALY saved. Estimated ICERs remained below AUD $40,000 per QALY saved throughout all sensitivity analyses, except when assuming the upper limit of the 95% confi dence interval for risedronate's effi cacy in reducing vertebral fracture risk (AUD $53,130 per QALY saved). CON-CLUSIONS: Risedronate represents a cost-effective option for preventing vertebral fractures in Australian patients with corticosteroid-induced osteoporosis. This was confi rmed by the recent recommendation by the Australian Pharmaceutical Benefi ts Advisory Committee (PBAC) that risedronate be reimbursed for this indication.
MUSCULAR-SKELETAL DISORDERS -Patient-Reported Outcomes Studies
PMS9
HEALTH-RELATED QUALITY OF LIFE IN INDIAN PATIENTS WITH RHEUMATOID ARTHRITIS
Khera K, Nagappa AN, Thunga G, Sam K Manipal College of Pharmaceutical Sciences, Manipal, India OBJECTIVES: Rheumatoid arthritis (RA) is a multisystem disease with various extraarticular manifestations (EAMs). Health-related quality of life (HRQOL) issues are assuming increasing importance in chronic rheumatic diseases like RA. Very less data on QOL in RA is available from the Indian subcontinent. There is also a paucity of literature on the impact of EAMs on HRQOL in RA. The objective of this study was to address these lacunae. METHODS: The study group comprised 166 patients with RA from a rheumatology clinic in India. Quality of life was estimated by the generic HRQOL measure: World Health Organization quality of life instrument (WHOQOL-Bref). Disease activity in RA was measured by calculating Disease Activity Score-28 (DAS28) and functional disability by the Health Assessment Questionnaire (HAQ). Extra-articular manifestations (EAMs) were diagnosed clinically. RESULTS: The mean duration of rheumatoid arthritis (RA) was 10 ± 3.1 years. The mean DAS28 and HAQ were 4.21 ± 1.1 and 1.01 ± 1.2, respectively. At least one ExRA was present in 46 patients. The mean HRQOL scores of the patients were 11.5 +/− 2.1, 12.2 +/− 2.5, 13.4 +/− 2.6, and 12.3 +/− 2.4 in the physical, psychological, social, and environmental domains of the WHOQOL-Bref respectively. Age, gender, disease duration, educational status, constitutional symptoms, rheumatoid factor positivity, erosions and deformities did not infl uence HRQOL. Disease activity had a negative infl uence on the physical and psychological domains. Patients with EAMs had significantly higher DAS28 scores compared to patients without EAMs. Even after adjustment for disease activity, patients with EAMs had lower HRQOL scores than patients without these features (statistically signifi cant for physical domain). CONCLUSIONS: The physical domain of HRQOL is most affected in Indian patients with RA. Increasing disease activity and presence of EAMs worsens the quality of life.
MUSCULAR-SKELETAL DISORDERS -Health Care Use & Policy Studies
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HEALTH-CARE UTILIZATION OF NEW PATIENTS WITH LOW BACK PAIN IN SOUTH KOREA
Kim JH, Lee SM, Cheong C, Jang B, Son HJ National Evidence-based Healthcare Collaborating Agency (NECA), Seoul, South Korea OBJECTIVES: The purpose of this study was to describe the pattern of health-care utilization among new patients with low back pain. METHODS: This study is based on the Korean National Health Insurance (NHI) claim data. Study subjects included those who 1) were newly diagnosed as low back pain; 2) received at least one lumbosacral spine simple x-ray; and 3) were not using medical service as a patient with low back pain for past 2 years before the fi rst visit (index date). The follow-up period was 1 year from the index date. RESULTS: New patients with low back pain used the clinic (81.8%) most and orthopedics (62.2%) was the most visited department in 2006. Ninety-six percent of new patients used outpatient service and 5.9% used inpatient service. The medical cost (paid by insurers) per patient was $215.1. Male expenses more than female, and the cost increased as the age of patients increased. Average days including medication days and days of visit per new patient with low back pain was 6.7 days with the tendency that female's average days including medication days and days of visit were more than those of male's. In terms of outpatient service, average days including medication days and days of visit per new patients was 5.8 days and in inpatient service, it was 15.8 days. CONCLUSIONS: Efforts to identify the factors which may produce low back pain and to reduce the incidence is on need. Also, analysis on the factors infl uential over the health-care use of new patients with low back pain needs to be conducted in future studies.
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HEALTH-CARE UTILIZATION OF PATIENTS WITH LOW BACK PAIN IN SOUTH KOREA (2006-2008)
Kim JH, Lee SM, Cheong C, Jang B, Son HJ National Evidence-based Healthcare Collaborating Agency (NECA), Seoul, South Korea OBJECTIVES: The objectives of this study were 1) to identify the pattern of healthcare use; and 2) to estimate the pattern change of health-care use for low back pain in each year of 2006, 2007, and 2008 . METHODS: This study is based on the Korean National Health Insurance (NHI) claim data. Study subjects included those who 1) used medical service as a patient with low back pain from January 1 to December 31, and 2) received at least one lumbosacral spine simple x-ray each year. The identifi ed number of the patients was 1,981,427 in 2006, 2,069,995 in 2007, and 2,119,408 in 2008 . RESULTS: Patients with low back pain used the clinic most and orthopedics was the most visited department in each year of 2006, 2007, and 2008 . The rate of outpatient service use declined and that of inpatient service use increased in compared 3 years. The medical cost (paid by insurers) showed increasing trend estimated as $569 million in 2006, $626 million in 2007, and $654 million in 2008 . However, if the infl ation rate of consumer price was considered (2.4% going up between 2006 and 2007, and 7.3% between 2006 and 2008) , the cost in 2007 was estimated as $611 million still showing increase, but, in 2008, $610 million was estimated showing decrease. Medical cost per patient was $287.2 in 2006, $295.2 in 2007, and $287.8 in 2008 . Average days including medication days and days of visit per patient was 9.4 days in 2006, 9.1 days in 2007, and 8.8 days in 2008 as declining. CONCLUSIONS: Efforts are needed to reduce prevalence and incidence of low back pain. And analysis on factors infl uential on the medical use of the patients needs to be conducted in future studies.
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INCREASE OF INJECTION THERAPY ON PATIENTS WITH LOW BACK PAIN IN SOUTH KOREA (2006-2008)
Kim JH, Lee SM, Cheong C, Jang B, Son HJ National Evidence-based Healthcare Collaborating Agency (NECA), Seoul, South Korea OBJECTIVES: The purposes of this study were 1) to analyze the pattern of injection therapy use for low back pain, and 2) to estimate the health-care use of low back pain patient who received injection therapy in 2006, 2007, and 2008 . METHODS: This study is based on the Korean National Health Insurance (NHI) claim data. Study subjects included those who 1) used medical service as a patients with low back pain from January 1 to December 31; 2) received at least one lumbosacral spine simple x-ray; and 3) took more than one injection therapy each year. RESULTS: The percent of patients with low back pain who received injection therapy was increasing as followed: 10.8% in 2006 (213,796 among total 1,981,427 patients with low back pain), 11.0% in 2007 (227,432 among 2,069,995), and 11.5% (244,640 among 2,119,408). Number of patients with low back pain treated with injections per 100,000 general population was 436 in 2006, 462 in 2007, and 494 in 2008 . Number of patients with low back pain treated with injections per 100,000 low back pain patients was 10,790 in 2006, 10,987 in 2007, and 11,543 in 2008 . The rate of patients who received one injection in a year was 58.9% in 2006, 52.5% in 2007, and 48.1% in 2008 showing tendency of decrease, while more than two injections was increasing. The most conducted procedure was Epidural Nerve Blocks consistently for 3 years. The most department visited for service was anesthesiology in 2006 and orthopedics in 2007 and 2008. CONCLUSIONS: The injection therapy on patients with low back pain is increasing. But the effi cacy of it has not reached to consensus so far, which means more careful conducting is needed. Also, the effi cacy of injection therapy specifi cally in South Korea should be investigated in future studies.
PMS14 FACTORS INFLUENCED ORAL OXICAM AND COXIBS' EXPENDITURE AT A THAI TEACHING HOSPITAL, FISCAL YEAR 2006-2009
Kaojarern S 1 , Masaya-anon N 1 , Pongcharoensuk P 2 , Pattanaprateep O 1 1 Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; 2 Mahidol University, Bangkok, Thailand OBJECTIVES: Oral Oxicam and Coxibs' expenditure at a Thai teaching hospital was rapidly increased in recent years. We examined price and quantity factors that infl uenced the rising expenditure by deterministic model. METHODS: This study was a retrospective database analysis at a Thai teaching hospital in Bangkok. Prescription utilization data of one oral Oxicam and two Coxibs (Meloxicam, Celecoxib, and Etoricoxib) during fi scal year 2006 to 2009 were retrieved. In the model, changes in annual expenditure were attributed to two factors: cost per patient per year (P) and number of patients per year (Q). By measuring quantity as Defi ned Daily Dose (DDD), changes in cost per patient (P) comprised of two parts: cost per DDD (p) and DDD per patient (q). RESULTS: Overall expenditure of the three drugs was risen from 49.9 million Baht in 2006 to 64.9 million Baht in 2009 (adjusted for infl ation). Thirty percent of total increase in expenditure was mainly the result of switching from Meloxicam (percent change, −44%) to Etoricoxib (119%). When decomposed into price and quantity factors, quantity had more effect than price, especially number of patients who moved from Meloxicam (percent change of Q, −35%) to Etoricoxib (112%) and Celecoxib (8%). DDD per patient for Celecoxib was a little increase (percent change of q, 4%), slightly decreased for Etoricoxib (−4%), and much lower for Meloxicam (−32%). Percent change in price of the three drugs was slightly positive (28%, 7%, and 8% for Meloxicam, Celecoxib, and Etoricoxib, respectively). CON-CLUSIONS: The major increase of drug expenditure from 2006 to 2009 was from
